Core Viewpoint - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. is actively engaging with institutional investors regarding its smoking cessation product, Varenicline Tartrate Tablets, highlighting its multi-channel sales strategy and market expansion efforts [1] Group 1: Product and Sales Strategy - The product utilizes a dual-brand strategy (Parique and Family Pharmacist) and a multi-channel sales model, covering over 100,000 chain stores and more than 600 hospitals, with online sales focused on platforms like JD, Alibaba, and Meituan [1] - Currently, the largest sales volume comes from offline chain channels, while hospital sales have not yet met company expectations [1] Group 2: Market Expansion and Effectiveness - The time to see results from entering new cities or regions depends on the execution and operational capabilities of the pharmacies, with effective pharmacies showing results in 2 to 3 months, while less capable ones may take longer [1] - Smokers typically see effects within days of using Varenicline Tartrate Tablets, but due to nicotine addiction's complex nature, there is a notable relapse rate, prompting the company to recommend adherence to the treatment regimen [1] Group 3: Competitive Landscape - The potential re-entry of Pfizer's smoking cessation drug into the Chinese market could enhance consumer awareness and market education, benefiting the overall market size due to Pfizer's strong brand influence and marketing capabilities [1]

Group 1: Sales Channels and Performance - The company’s smoking cessation drug, Varenicline Tartrate Tablets, utilizes a dual-brand strategy (PariKe and Family Pharmacist) and multiple sales channels, including over 100,000 chain stores and more than 600 hospitals, with online sales primarily through JD, Alibaba, and Meituan [2] - The largest sales volume for the smoking cessation drug currently comes from offline chain channels [2] - Sales in hospital channels have not met company expectations, as most hospitals only have smoking cessation clinics available for one or two half-days a week [3] Group 2: Market Expansion and Effectiveness - The time required to see results from expanding the drug to new cities or regions depends on the pharmacy's execution; well-managed pharmacies may show improvement in 2 to 3 months, while others may take longer [3] - Smokers using Varenicline Tartrate Tablets generally see effects within a few days, but a significant proportion experience relapse due to various physiological and psychological factors [3] Group 3: Competitive Landscape - If Pfizer re-enters the Chinese market with its smoking cessation drug, the company believes it would positively impact the market by increasing consumer awareness and expanding the overall market size [3]

Market Expansion - As of June 2025, the company's smoking cessation drug, varenicline tartrate tablets, has entered over 100,000 retail stores in the OTC market, with a target of exceeding 140,000 stores by the end of 2025 and 250,000 stores by the end of 2026 [2][3] Market Capacity - The smoking cessation drug market in China has a significant potential, with over 300 million smokers, and the company aims to cover 50 million smokers over the next 10 years [2] User Demographics - The user demographic for varenicline tartrate tablets spans all age groups, with the highest proportion being male smokers in their 30s [3] Cost of Treatment - The estimated cost for each smoker using the varenicline tartrate tablets for a 3-month treatment course is no more than RMB 2,000 [3] Shareholding and Future Plans - The company acknowledges that its major shareholders have a relatively low holding percentage and plans to promote a stock issuance project to specific investors [3]